Schaefer R M, Kuerner B, Zech M, Denninger G, Borneff C, Heidland A
Department of Internal Medicine, University of Wuerzburg, FRG.
Int J Artif Organs. 1988 Jul;11(4):249-54.
Fifteen long-term hemodialysis patients suffering from stable anemia received recombinant human erythropoietin (r-huEPO). The hormone was given intravenously at the end of each dialysis session starting with a dose of 24 IU/kg. This dose was doubled when hemoglobin levels did not rise within 2 weeks. The number of reticulocytes started to increase after 14 days of treatment. The hematocrit rose from baseline values of 23.7 +/- 1.2% to 32.4 +/- 1.3% after 24 weeks of treatment. In parallel, hemoglobin values increased from 7.3 +/- 0.3 g/100 ml to 10.1 +/- 0.4 g/100 ml. As for side effects, 3 patients developed hypertension and 2 patients suffered from occlusions of their arterio-venous fistulas. There was no evidence of major organ dysfunctions, toxic effects, allergic reactions, or antibody formation. These data show that r-HuEPO is able to correct the anemia of patients undergoing hemodialysis treatment.
15名患有稳定型贫血的长期血液透析患者接受了重组人促红细胞生成素（r-huEPO）治疗。在每次透析结束时静脉注射该激素，起始剂量为24国际单位/千克。如果血红蛋白水平在2周内未升高，则将该剂量加倍。治疗14天后，网织红细胞数量开始增加。治疗24周后，血细胞比容从基线值23.7±1.2%升至32.4±1.3%。同时，血红蛋白值从7.3±0.3克/100毫升增至10.1±0.4克/100毫升。至于副作用，3名患者出现高血压，2名患者发生动静脉内瘘闭塞。没有证据表明存在主要器官功能障碍、毒性作用、过敏反应或抗体形成。这些数据表明，r-HuEPO能够纠正接受血液透析治疗患者的贫血。
